



ASX release

17 February 2016

## Patent granted in Japan

AtCor Medical (ASX: ACG), the developer and marketer of the SphygmoCor® system which measures central aortic blood pressures and arterial stiffness noninvasively, today announced that it has been granted a new patent “*Brachial Cuff*” in Japan. This establishes a proprietary position for AtCor in measuring central aortic pressure waveforms using a standard brachial cuff with a transfer function, and confers intellectual property rights to AtCor until November 2032.

A transfer function is the only proven methodology to non-invasively derive all central pressure waveform features. These are directly related to cardiovascular function and ensure equivalence to invasive measurement of central aortic pressures. SphygmoCor pioneered this application of a transfer function and its intellectual property continues to protect the company from competitors replicating its precision. This patent further extends SphygmoCor competitive advantage.

“This patent locks in significant competitive advantage for AtCor”, said AtCor Medical CEO Duncan Ross. “Being awarded this patent continues our progress in Japan, following appointment of our distribution partner A&D Company Limited which is already marketing SphygmoCor XCEL to the medical community. With central pressures being added to the Japanese Society of Hypertension Guidelines in 2014, this further strengthens our position in the world’s second largest medical device market.”

An application for the same patent is well advanced in USA.

### About AtCor Medical

AtCor Medical develops and markets products for the early detection of cardiovascular risk and management of cardiovascular disease. Its technology allows researchers and clinicians to measure central blood pressure non-invasively. The company’s SphygmoCor® system visibly identifies the effects of reflected blood pressure in the central aortic pressure wave, effects which cannot be detected with standard blood pressure monitoring. More than 4,000 SphygmoCor® systems are currently in use worldwide at major medical institutions, research institutions and in various clinical trials with leading pharmaceutical companies. The company’s technology has been featured in over 900 peer-reviewed studies published in leading medical journals. AtCor has operations in Australia, the United States, and Europe. For further information, please visit our web site at [www.atcormedical.com](http://www.atcormedical.com).

*For further information, please contact:*

Duncan Ross – AtCor Medical CEO  
+1 (630) 228 8873

Peter Manley – AtCor Medical CFO  
+61 (2) 8815 8811  
[p.manley@atcormedical.com](mailto:p.manley@atcormedical.com)

*Media enquiries to:*

Ashley Rambukwella – Financial &  
Corporate Relations  
Ph: +61 (2) 8264 1004/ m.0407 231 282 or  
[a.rambukwella@fcr.com.au](mailto:a.rambukwella@fcr.com.au)